When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HCM - Hutchmed begins dosing in early-stage study of cancer drug HMPL-A83
HUTCHMED (China) Limited
Hutchmed (China) ( NASDAQ: HCM ) said it began a phase 1 trial of HMPL-A83 in patients with advanced malignant neoplasms in China.
The first patient received their first dose on July 15.
The phase 1 study will evaluate the safety and preliminary efficacy of HMPL-A83 in patients with advanced malignant neoplasms and also find a phase 2 dose and maximum tolerated dose.
Malignant neoplasms are cancerous tumors that can also spread to other parts of the body.